Study authors identified two congress abstracts and nine randomized controlled trials: eight of which were related to undifferentiated arthritis, and one which was related to very early RA.
Four Phase 3 clinical trials of baricitinib in the treatment of moderate-to-severe active rheumatoid arthritis enrolled patients who were methotrexate-naïve or had inadequate response to methotrexate, conventional disease-modifying antirheumatic drugs (DMARDs) or DMARDs with TNF inhibitors.
Krystexxa, a PEGylated uric acid specific enzyme, is approved for the treatment of refractory chronic gout.
Simponi Aria is currently approved for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.
The SPIRIT-P2 trial will continue to evaluate long-term efficacy and safety of Taltz in PsA for up to 3 years.
This first-of-its-kind study followed 16 patients at ≥30 weeks gestation who have been on Cimzia therapy for RA (n=11), CD (n=3), PsA (n=1), or axSpA/AS (n=1).
Romosozumab, a monoclonal antibody, binds and inhibits sclerostin.
Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate.
The VOLTAIRE-RA study enrolled 645 adults aged 18-80 years with moderately-to-severely active rheumatoid arthritis on stable therapy with methotrexate.
Want to read more?
Please login or register first to view this content.